Christal G. Delagrammatikas

Christal G. Delagrammatikas

Auto-generated profile, based on publicly available information

Christal G. Delagrammatikas

Malan Syndrome Foundation, Old Bridge, NJ, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2025 in Disease Models & Mechanisms
Verified
Journal Article
Open access
CACooper Atterton
Cooper Atterton
ITIsabella Trew
Isabella Trew
JCJessica M. Cale
Jessica M. Cale
MAMay T. Aung-Htut
May T. Aung-Htut
KGKerry Grens
Kerry Grens
MPMichael Piper
Michael Piper
Overgrowth-intellectual disability (OGID) syndromes encompass a group of rare neurodevelopmental disorders that frequently share common clinical presentations. Although the genetic causes of many OGID syndromes are now known, we lack a clear mechanistic understanding of how such variants disrupt developmental processes and ultimately culminate in overgrowth and neurological symptoms. Patient advocacy groups, such as the Overgrowth Syndromes Alliance (OSA), are mobilising patients, families, clinicians and researchers to work together towards a deeper understanding of the clinical needs of patients with OGID, as well as to understand the fundamental biology of the relevant genes, with the goal of developing treatments. In this Review, we summarise three OGID syndromes encompassed by the OSA, namely Sotos syndrome, Malan syndrome and Tatton-Brown-Rahman syndrome. We discuss similarities and differences in the biology behind each disorder and explore future approaches that could potentially provide a way to ameliorate some of the unmet clinical needs of patients with OGID.

31 May 2024 in Therapeutic Advances in Rare Disease
Verified
Journal Article
Open access
KGKerry Grens
Kerry Grens
KCKit M. Church
Kit M. Church
EDEric Diehl
Eric Diehl
SHSenyene E. Hunter
Senyene E. Hunter
KTKatrina Tatton-Brown
Katrina Tatton-Brown
CDChristal G. Delagrammatikas
Christal G. Delagrammatikas
Overgrowth–intellectual disability (OGID) syndromes are a collection of rare genetic disorders with overlapping clinical profiles. In addition to the cardinal features of general overgrowth (height and/or head circumference at least two standard deviations above the mean) and some degree of intellectual disability, the OGID syndromes are often associated with neurological anomalies including seizures. In an effort to advance research in directions that will generate meaningful treatments for people with OGID syndromes, a new collaborative partnership called the Overgrowth Syndromes Alliance (OSA) formed in 2023. By taking a phenotype-first approach, OSA aims to unite research and patient communities traditionally siloed by genetic disorder. OSA has galvanized OGID patient organizations around shared interests and developed a research roadmap to identify and address our community’s greatest unmet needs. Here, we describe the literature regarding seizures among those with overgrowth syndromes and present the OSA Research Roadmap. This patient-driven guide outlines the milestones essential to reaching the outcome of effective treatments for OGID syndromes and offers resources for reaching those milestones.

22 September 2025 in Journal of Child Neurology
Verified
Journal Article
Closed access
SDSweta Dubey
Sweta Dubey
SHSenyene E. Hunter
Senyene E. Hunter
CDChristal G. Delagrammatikas
Christal G. Delagrammatikas
GPGloria Pinero
Gloria Pinero
VEVimala Elumalai
Vimala Elumalai
MZMuhammad Shahzad Zafar
Muhammad Shahzad Zafar
Malan syndrome is an ultrarare overgrowth–intellectual disability syndrome caused by NFIX variants, characterized by intellectual disability, postnatal overgrowth, and dysmorphic features. Seizures in Malan syndrome remain poorly understood. We surveyed caregivers of 53 individuals with Malan syndrome. Overall, 55% had seizures or electroencephalographic (EEG) abnormalities. Seizures occurred in 47%, with 28% experiencing drug-resistant epilepsy. The median age of seizure onset was 3 years. Epilepsy classifications included focal (40%) and unknown-onset tonic-clonic seizures (48%). Generalized tonic-clonic (8%), myoclonic (8%), and epileptic spasms (4%) were also reported. Of those with seizures, 44% had status epilepticus. Valproic acid was the most used antiseizure medication, with variable efficacy. This study represents the largest cohort to date, providing detailed descriptions of seizures in Malan syndrome, and lays a foundation for future research phenotyping epilepsy in affected individuals. Clinicians should maintain a high suspicion of seizures and monitor closely for status epilepticus in individuals with Malan syndrome.

19 July 2026 in medRxiv
Verified
Preprint
Open access
PDF file
CDChristal G. Delagrammatikas
Christal G. Delagrammatikas
LGLouise Gourlay
Louise Gourlay
Manuela PrioloManuela Priolo
Manuela Priolo
RRRosaria RUSSO
Rosaria RUSSO
AAAmirsadra Ahmadi
Amirsadra Ahmadi
BCBenjamin T. Cocanougher
Benjamin T. Cocanougher
Purpose: Pathogenic variants in NFIX cause Marshall-Smith syndrome and Malan syndrome (MALNS). We identified a severe subtype of MALNS characterized by adolescent-onset musculoskeletal deterioration and investigated functional consequences of underlying variants. Methods: Clinical data were collected from seven individuals with pathogenic NFIX variants. Wild-type and mutated recombinant NFIX DNA-binding domains (DBDs) were evaluated using biochemical, structural, and DNA-binding assays. Results: Six individuals carrying R116W, R116P, K125E, or G147E NFIX substitutions developed progressive muscle wasting, markedly reduced body mass index, and rapidly progressive scoliosis after the typical childhood features of MALNS; two died from disease-related complications. A seventh individual with R116G did not develop this severe phenotype. Functional studies on recombinant NFIX DBDs showed complete or near-complete loss of DNA-binding activity for R116W, R116P, K125E, and G147E despite preserved protein folding, consistent with disrupted DNA recognition and a potential dominant-negative mechanism. In contrast, R116G exhibited a 7.7°C decrease in thermal stability, which may support haploinsufficiency mediated by protein degradation. Conclusion: Specific NFIX missense variants define a severe subtype of MALNS associated with progressive musculoskeletal deterioration. In vitro functional studies support variant-specific disruption of DNA binding, providing a mechanistic basis of genotype-phenotype correlations and informing prognosis, clinical surveillance, and therapy development.